{"id":"cbacbe43-2488-5980-b22a-24c8b23e9386","stable_key":"4910e17b-aaec-52cd-b9e5-caca85d817ee:red-yeast-rice-lipocol-dose-response","predicate":"has_dose_related","statement":"In 14 volunteers, single doses of one, two or four LipoCol Forte capsules produced dose-related lovastatin and lovastatin-acid exposure; one capsule twice daily for five days produced no significant accumulation.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"87abf4c9-48b2-575d-9cd0-8ee88f895716","mechanism_event_label":"The measured product had a defined short-term exposure profile.","subject":{"id":"30978ef1-162a-52bd-bb88-2e506565f5bc","slug":"lipocol-forte-2012","display_name":"LipoCol Forte red yeast rice preparation studied in 2012","entity_type_key":"drug"},"object":{"id":"5dcb50cd-6f97-5bb5-806c-277c8a5fed88","slug":"human-lovastatin-acid-plasma-exposure","display_name":"Human plasma exposure to lovastatin hydroxy acid","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"87abf4c9-48b2-575d-9cd0-8ee88f895716","stable_key":"4910e17b-aaec-52cd-b9e5-caca85d817ee:red-yeast-rice-lipocol-dose-response-event","event_type":"observed_relationship","label":"The measured product had a defined short-term exposure profile.","description":"In 14 volunteers, single doses of one, two or four LipoCol Forte capsules produced dose-related lovastatin and lovastatin-acid exposure; one capsule twice daily for five days produced no significant accumulation.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"30978ef1-162a-52bd-bb88-2e506565f5bc","slug":"lipocol-forte-2012","display_name":"LipoCol Forte red yeast rice preparation studied in 2012","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"5dcb50cd-6f97-5bb5-806c-277c8a5fed88","slug":"human-lovastatin-acid-plasma-exposure","display_name":"Human plasma exposure to lovastatin hydroxy acid","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"5d0ea9bb-cce8-5e13-aa3d-37db2215386e","slug":"lovastatin","display_name":"Lovastatin / monacolin K lactone","entity_type_key":"drug"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"bd3bb602-9a12-5d58-8130-538236270e6f","slug":"lovastatin-acid","display_name":"Lovastatin hydroxy acid / monacolin KA","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"d4154949-85ce-5c98-9f32-af94e72d613a","slug":"human-lovastatin-plasma-exposure","display_name":"Human plasma exposure to lovastatin","entity_type_key":"cellular_process"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_access","value_text":"Primary full text PMC3513969","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Human fed-state dose and repeat-dose study; 600 mg per capsule.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Does not establish identical kinetics for other formulations, chronic use or interacting-drug conditions.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Red yeast rice collection; species, compartment, exposure, co-substrates and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"red-yeast-rice","display_name":"Red yeast rice","entity_type_key":"chemical_species"}},{"dimension":"plain_language","value_text":"The measured product had a defined short-term exposure profile.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[23227093] Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin. · 2012 · https://pubmed.ncbi.nlm.nih.gov/23227093/ · DOI 10.1155/2012/127043","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"e8c2a971-4c45-5956-bbf6-411fb8e4ed58","evidence_kind":"source_excerpt","locator":"Lines 148-154","start_line":148,"end_line":154,"excerpt":"## red-yeast-rice-lipocol-dose-response\nThe measured product had a defined short-term exposure profile.\nIn 14 volunteers, single doses of one, two or four LipoCol Forte capsules produced dose-related lovastatin and lovastatin-acid exposure; one capsule twice daily for five days produced no significant accumulation.\nModel: Human fed-state dose and repeat-dose study; 600 mg per capsule.\nLimitations: Does not establish identical kinetics for other formulations, chronic use or interacting-drug conditions.\nEvidence access: Primary full text PMC3513969\n[23227093] Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin. · 2012 · https://pubmed.ncbi.nlm.nih.gov/23227093/ · DOI 10.1155/2012/127043","model_system":"Human fed-state dose and repeat-dose study; 600 mg per capsule.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"261a12bc-3d00-52a4-a5ec-70e174390596","stable_key":"import-4910e17b-aaec-52cd-b9e5-caca85d817ee","title":"Red yeast rice: constituents, mevalonate, CoQ and product-specific interactions (2026-09-20)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"271bbcecaaacc76ad4d06718ae592dc6a1b33e3e459adfdd36cbd0ac5f09c0f6","revision_id":"9c30956c-206c-5c49-ae42-81b070088e26","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}